Health Care Flat Amid Deal Activity -- Health Care Roundup

Dow Jones03-25 05:30

Health-care companies were more or less flat, amid deal activity.

Gilead Sciences plans to acquire Ouro Medicines, a developer of autoimmune-disease therapies, for up to about $2.18 billion and develop the assets from the deal in a collaboration with Galapagos.

Shares of ImmunityBio plummeted after the Food and Drug Administration said the biotech company used false or misleading advertising to promote Anktiva, its flagship bladder cancer drug.

CVS Health and Federal Trade Commission staff have reached a proposed agreement to resolve insulin litigation in which the agency accused pharmacy-benefit managers, or PBMs, of artificially inflating insulin prices.

Write to Rob Curran at rob.curran@dowjones.com

(END) Dow Jones Newswires

March 24, 2026 17:30 ET (21:30 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622016567?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-25 05:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622016567","market":"other","top_or_hot":-1,"title":"Health Care Flat Amid Deal Activity -- Health Care Roundup","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  Health-care companies were more or less flat, amid deal activity. \n</p>\n<p>\n  <a href=\"https://laohu8.com/S/GILD\">Gilead</a> Sciences plans to acquire Ouro Medicines, a developer of autoimmune-disease therapies, for up to about $2.18 billion and develop the assets from the deal in a collaboration with Galapagos. \n</p>\n<p>\n  Shares of ImmunityBio plummeted after the Food and Drug Administration said the biotech company used false or misleading advertising to promote Anktiva, its flagship bladder cancer drug. \n</p>\n<p>\n  CVS Health and Federal Trade Commission staff have reached a proposed agreement to resolve insulin litigation in which the agency accused pharmacy-benefit managers, or PBMs, of artificially inflating insulin prices. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Rob Curran at rob.curran@dowjones.com \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 24, 2026 17:30 ET (21:30 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Health Care Flat Amid Deal Activity -- Health Care Roundup</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHealth Care Flat Amid Deal Activity -- Health Care Roundup\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-03-25 05:30</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  Health-care companies were more or less flat, amid deal activity. \n</p>\n<p>\n  <a href=\"https://laohu8.com/S/GILD\">Gilead</a> Sciences plans to acquire Ouro Medicines, a developer of autoimmune-disease therapies, for up to about $2.18 billion and develop the assets from the deal in a collaboration with Galapagos. \n</p>\n<p>\n  Shares of ImmunityBio plummeted after the Food and Drug Administration said the biotech company used false or misleading advertising to promote Anktiva, its flagship bladder cancer drug. \n</p>\n<p>\n  CVS Health and Federal Trade Commission staff have reached a proposed agreement to resolve insulin litigation in which the agency accused pharmacy-benefit managers, or PBMs, of artificially inflating insulin prices. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Rob Curran at rob.curran@dowjones.com \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 24, 2026 17:30 ET (21:30 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XLV","symbol_name":"健康照护类股ETF-SPDR","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2622016567","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622016567","pubTimestamp":1774387800,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Health-care companies were more or less flat, amid deal activity.Gilead Sciences plans to acquire Ouro Medicines, a developer of autoimmune-disease therapies, for up to about $2.18 billion and develop the assets from the deal in a collaboration with Galapagos.Shares of ImmunityBio plummeted after the Food and Drug Administration said the biotech company used false or misleading advertising to promote Anktiva, its flagship bladder cancer drug.CVS Health and Federal Trade Commission staff have reached a proposed agreement to resolve insulin litigation in which the agency accused pharmacy-benefit managers, or PBMs, of artificially inflating insulin prices.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"XLV":"健康照护类股ETF-SPDR","BK4588":"碎股","XBI":"SPDR S&P Biotech ETF","LABU":"三倍做多标普生物-Direxion","BK4585":"ETF&股票定投概念","BK4581":"高盛持仓"},"translate_title":"医疗保健在交易活动中持平——医疗保健综述","themeId":"8603dabb40994e59ac78c04c930c0d49","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XBI":0.6,"XLV":1.5,"LABU":0.6},"content_text":"Health-care companies were more or less flat, amid deal activity. \n\n\nGilead Sciences plans to acquire Ouro Medicines, a developer of autoimmune-disease therapies, for up to about $2.18 billion and develop the assets from the deal in a collaboration with Galapagos. \n\n\n  Shares of ImmunityBio plummeted after the Food and Drug Administration said the biotech company used false or misleading advertising to promote Anktiva, its flagship bladder cancer drug. \n\n\n  CVS Health and Federal Trade Commission staff have reached a proposed agreement to resolve insulin litigation in which the agency accused pharmacy-benefit managers, or PBMs, of artificially inflating insulin prices. \n\n\n \n\n\n  Write to Rob Curran at rob.curran@dowjones.com \n\n\n  (END) Dow Jones Newswires\n\n\n  March 24, 2026 17:30 ET (21:30 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622016567","isCrawlerRequest":true}